Clementia Pharmaceuticals Inc. (CMTA)
(Delayed Data from NSDQ)
$26.35 USD
0.00 (0.00%)
Updated Apr 17, 2019 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[CMTA]
Reports for Purchase
Showing records 1 - 20 ( 28 total )
Industry: Medical - Biomedical and Genetics
Dropping coverage Due to Announced Acquisition
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
D/g to Neutral: French Kiss with a Kick; Ipsen Acquires CMTA for $25/Share +CVR
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
2019 TOP IDEAS-Healthcare Sector Review Preview.
Provider: Bloom Burton & Company
Industry: Medical - Biomedical and Genetics
We are initiating research coverage with a BUY rating (Speculative Risk) and a 12-month target price of $18.00
Provider: Bloom Burton & Company
Analyst: MARTIN D
Industry: Medical - Biomedical and Genetics
De-Risked But Under-loved, We?re Buyers for 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
PVO Stacks Lineup with Ph 3 and pre-NDA in FOP, Ph 2 in MO, and Ph 1 in Dry Eye
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
To Submit Palovarotene NDA for FOP in 2H19 Following Positive FDA Feedback
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for CMTA
Provider: ValuEngine, Inc
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Industry: Medical - Biomedical and Genetics
Updated Ph 2 Part B Data Highlights Importance of Flare-up Protocol in Ph 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Unclassified
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
2Q18 Financials; Development Programs on Track, Share Weakness Overblown
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
2Q18 Financials; Development Programs on Track, Share Weakness Overblown
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Industry: Unclassified
12mo Part B Data Provides Good Readthrough to MOVE
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Industry: Unclassified
Ph 3 Accrual MOVEing Along Nicely, Part B Catalyst Still to Come This Quarter
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D